- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03741322
A 24 Month Observational Study of Infants 3-24 Months, Who Suffer an Acute Episode of Respiratory Infection and Wheezing Illness (BIOPA)
24 de novembro de 2020 atualizado por: Duke University
Respiratory BIOmarkers in Viral Wheezing That Predict Asthma
This study will identify infants between the age of 3 and 24 months of age who are experiencing one of their first acute respiratory infections with confirmed wheezing.
Infants who are also confirmed to be wheezing and whose caregiver signs consent will be enrolled from a primary care clinic, emergency room or hospital.
Visão geral do estudo
Status
Concluído
Condições
Descrição detalhada
BACKGROUND: Respiratory virus infections are extremely common in young children.
These infections typically lead to inflammation and constriction of the airways, which is termed bronchiolitis.
Bronchiolitis is the leading cause of hospitalization for infants with respiratory infections, with an average of 120,000 children under the age of one hospitalized every year.
Viral infection by Respiratory Syncytial Virus (RSV), rhinoviruses, or influenza viruses is thought to be by far the major driver of bronchiolitis.
The children who need to be hospitalized with bronchiolitis have a drastically increased chance (about 45%) of developing chronic respiratory diseases such as wheezing or asthma.
The disease of asthma affects children more than adults, and the Centers For Disease Control states that asthma is the most chronic condition among children under the age of 18, affecting more than 6 million (or 8.4%) children in the US.
Due to this prevalence, asthma is the third leading cause of hospitalization among children under the age of 15 years, with the annual direct healthcare costs at ~$50 billion every year.
The economic costs associated with parental lost productivity is another ~$6 billion every year.
The American Lung Association states that asthma is also one of the leading causes of school absenteeism, with an estimated 13.8 million lost school days every year.
While asthma can be managed with bronchodilator inhalers, there is not a single treatment designed to prevent or reverse asthma disease.
Understanding how viral infection causes initial bronchiolitis and maintains the chronic inflammation that leads to asthma will lead to new treatments that prevent or reverse chronic lung diseases.
This research has the potential to change everyday life for millions of children and their families in the US.
Tipo de estudo
Observacional
Inscrição (Real)
5
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27710
- Duke University Medical Center
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
3 meses a 2 anos (Filho)
Aceita Voluntários Saudáveis
N/D
Gêneros Elegíveis para o Estudo
Tudo
Método de amostragem
Amostra Não Probabilística
População do estudo
Participants will be offered enrollment into the study via Institutional Review Board-approved methods including review of newly hospitalized patients to Duke Children's Hospital, patients seen in the Duke Children's Hospital Emergency Room, and patients seen in a Duke Children's ambulatory clinics.
Consent: The study will be explained to the participant and caregiver by trained study staff (Principal Investigator, Co-Investigator, research coordinator or research assistant).
Descrição
Inclusion Criteria:
- Documented informed consent from legal guardian prior to study procedures
- Age: 3-24 months at the time of visit 1
- Severe lower respiratory wheezing illness confirmed by auscultation requiring hospitalization or acute care (Emergency Department care or unscheduled ambulatory care)
Exclusion Criteria:
- No prior hospital admissions for wheezing illnesses
- No prior diagnosis of asthma or Reactive Airways Disease
- More than 1 prior episode of wheezing confirmed by auscultation
- No congenital or chronic disease which would negatively affect the conduct of the study (e.g. childhood cancer, cystic fibrosis, interstitial lung disease, prior aero-digestive surgery)
- No diagnosis of bronchopulmonary dysplasia
- No premature birth (gestational age < 32 weeks)
- Daily treatment with a daily asthma controller (e.g. Montelukast, inhaled corticosteroid)
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
---|
Infants ages 3-24 months with respiratory infections
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Persistent Asthma Phenotype (PAP)
Prazo: Measured at 24 months
|
Participants will be assessed for meeting criteria for the persistent asthma phenotype which will be defined as meeting any Asthma Predicative Indices plus abnormal lung pulmonary function testing by Impulse oscillometry (either from peripheral airway resistance or bronchodilator responsiveness).
|
Measured at 24 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Total confirmed Respiratory tract infections as measured by nasal secretion sampling.
Prazo: Up to 24 months
|
Up to 24 months
|
|
Pulmonary Function Testing (iPFT)
Prazo: Measured at 24 months
|
Impulse Oscillometry (IOS) simply requires the child to breathe in and out through a mouthpiece for 20-30 seconds.
During breathing, a loudspeaker delivers a quiet pulse-shaped pressure-flow signal to the respiratory system.
The overall respiratory system impedance (Z) is measured and reflects the resistive and viscoelastic forces of the respiratory system determined from the returning signal.
Outcome data are reported as respiratory system resistance (R) and reactance (X) measured in centimeters of water per liter per second.
Measurements from the 3 efforts for each outcome parameter will be averaged for the final result.
|
Measured at 24 months
|
Presence or absence of Loose Asthma Predictive Indices
Prazo: 24 months
|
Lose API is based on based on any wheezing in first 3 years of life plus, One of the following two: Parental asthma or child eczema, AND Two of the following three: eosinophilia, wheezing without colds, and allergic rhinitis.
|
24 months
|
Presence or absence of Strict Criteria for API
Prazo: 24 months
|
Strict API is measured based on Early Frequent wheezing in first 3 years of life plus, One of the following two: Parental asthma or child eczema, AND Two of the following three: eosinophilia, wheezing without colds, and allergic rhinitis.
|
24 months
|
Presence or absence of Modified API
Prazo: 24 months
|
Modified API is measured based on ≥4 wheezing episodes in a year plus, One of the following two: Parental asthma or child eczema or allergic sensitization to at least one aeroallergen, AND Two of the following three: eosinophilia, wheezing without colds, and allergic sensitization to milk, egg or peanuts.
|
24 months
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Jason Lang, MD, MPH, Duke University
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
12 de dezembro de 2018
Conclusão Primária (Real)
16 de junho de 2020
Conclusão do estudo (Real)
16 de junho de 2020
Datas de inscrição no estudo
Enviado pela primeira vez
25 de outubro de 2018
Enviado pela primeira vez que atendeu aos critérios de CQ
12 de novembro de 2018
Primeira postagem (Real)
14 de novembro de 2018
Atualizações de registro de estudo
Última Atualização Postada (Real)
25 de novembro de 2020
Última atualização enviada que atendeu aos critérios de controle de qualidade
24 de novembro de 2020
Última verificação
1 de novembro de 2020
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- Pro00100494
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .